Rebiotix Announces New RBX2660 Data Including a Novel Microbiome Biomarker Analysis to be Presented at the World Congress of Gastroenterology at ACG2017

ROSEVILLE, Minn., Oct. 12, 2017 /PRNewswire/ -- Rebiotix Inc., a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to treat challenging diseases, today announced that three posters have been accepted for presentation at the World Congress of Gastroenterology at ACG2017 being held October 13^th-18^th in Orlando, Florida.  The posters will feature new clinical findings from RBX2660 Phase 2 studies, including analyses of microbiome changes in patients who received Rebiotix's lead drug in its Microbiota Restoration Therapy™ platform.  Additionally, researchers will present new Rebiotix-sponsored biomarker research aimed at developing a human Microbiome Health Index (MHI)™. 

RBX2660 is currently being evaluated in an international Phase 3 clinical trial for the prevention of recurrent Clostridium difficile infection (C. diff.).

The schedule of presentations is as follows:

About Clostridium difficile Infection
Clostridium difficile (C. diff.) infection is a serious and potentially fatal gastrointestinal disease, characterized by severe diarrhea, fever, and loss of appetite. It is a leading healthcare-associated infection (HAI), and in the U.S. alone, there are about 500,000 people infected and over 29,000 deaths annually from the disease. Currently, 20-30% of patients with C. diff. go on to experience more than one episode of the disease, which is known as recurrent C. diff. infection. Recurrent C. diff. infection is especially challenging to treat as, to date, there are no approved microbial-based drugs to treat patients with two or more recurrences.

About Rebiotix Inc.
Rebiotix Inc. is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection.  RBX2660 has been granted Fast Track status and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff. infection. Rebiotix's clinical pipeline also features RBX7455, a lyophilized non-frozen, oral capsule formulation, which is currently the subject of an investigator-sponsored Phase 1 trial for the prevention of recurrent C. diff. infection.  In addition, Rebiotix is targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy^™ (MRT) platform.  MRT is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient's intestinal tract via a ready-to-use and easy-to-administer format. For more information on Rebiotix and its pipeline of human microbiome-directed therapies, visit www.rebiotix.com.

Rebiotix Media Contact:
Jason Rando
Tiberend Strategic Advisors, Inc.
212-375-2665
[email protected]

SOURCE Rebiotix Inc.

Related Links

http://www.rebiotix.com